Abstract:There is increasing evidence that many human cancers, including breast cancer, are driven and maintained by cancer stem cells (CSCs) which mediate tumor metastasis and contribute to treatment resistance and relapse. Our group was the first to describe “breast cancer stem cells” (BCSCs) characterized by expression of the cell surface markers ESA and CD44 and the absence of expression of the marker CD24. More recently, we have demonstrated that breast cancer cells contain subpopulations with stem cell properties that can be isolated by virtue of their expression of Aldehyde dehydrogenase (ALDH) as assessed by the Aldefluor assay. Interestingly, these markers identify overlapping, but not identical cell populations. Recent studies have suggested similarities between cancer stem cells and the epithelial mesenchymal transition (EMT) state. Our studies suggest that both normal and malignant breast stem cells exist in distinct, inter-convertible states (EMT and MET), the inter-conversion of which is regulated by microRNAs. EMT-like CSCs have a mesenchymal morphology, are largely quiescent, invasive and characterized by expression of the CSC markers CD24 - CD44 + and are EpCAM - CD49f + . In contrast, the MET (mesenchymal epithelial transition) state of CSCs is characterized by active self-renewal and expression of the CSC markers ALDH and EpCAM + CD49f + . A subpopulation of cells expressing both CD24 - CD44 + and ALDH may represent cells in transition between these states. This transition is regulated by signals originating in the microenvironment which in turn modulate microRNA networks in the CSC populations. The existence of multiple stem cell states suggests the necessity of developing therapeutic strategies capable of effectively targeting CSCs in all of these states. In addition, since CSC states are regulated by miRNAs, these small non-coding RNAs may be useful therapeutic agents to target CSCs.

Novel Molecular Regulators of Breast Cancer Stem Cell Plasticity and Heterogeneity

Stem Cells and Cellular Origins of Breast Cancer: Updates in the Rationale, Controversies, and Therapeutic Implications

Advances in Biomarkers and Endogenous Regulation of Breast Cancer Stem Cells.

Heterogeneity in cancer stem cells.

Cancer Stem Cells: Constantly Evolving and Functionally Heterogeneous Therapeutic Targets.

Role of microRNAs in the Regulation of Breast Cancer Stem Cells

Breast Cancer Stem Cells: Biomarkers, Identification and Isolation Methods, Regulating Mechanisms, Cellular Origin, and Beyond

Heterogeneity of BCSCs contributes to the metastatic organotropism of breast cancer

Role, Molecular Mechanism and the Potential Target of Breast Cancer Stem Cells in Breast Cancer Development

Single-cell transcriptomics reveal the heterogeneity and dynamic of cancer stem-like cells during breast tumor progression

Breast Cancer Stem Cells Transition Between Epithelial and Mesenchymal States Reflective of Their Normal Counterparts

Long Non-Coding RNAs as Regulators for Targeting Breast Cancer Stem Cells and Tumor Immune Microenvironment: Biological Properties and Therapeutic Potential

A physical mechanism of heterogeneity in stem cell, cancer and cancer stem cell

Targeting Epigenetic Modifiers of Tumor Plasticity and Cancer Stem Cell Behavior

Heterogeneity in Circulating Tumor Cells: The Relevance of the Stem-Cell Subset

Breast cancer stem cells: current advances and clinical implications.

The Roles of Ncrnas and Histone-Modifiers in Regulating Breast Cancer Stem Cells

Complex interaction and heterogeneity among cancer stem cells in head and neck squamous cell carcinoma revealed by single-cell sequencing

Preclinical and Clinical Trials of New Treatment Strategies Targeting Cancer Stem Cells in Subtypes of Breast Cancer

Heterogeneity of Cancer Stem Cells in Tumorigenesis, Metastasis, and Resistance to Antineoplastic Treatment of Head and Neck Tumours

Cancer stem cells and the tumor microenvironment: interplay in tumor heterogeneity